A treatment that addresses not only obesity, but also improves lipid profiles, blood pressure, glycemic control and inflammation, could potentially reduce the risk of cardiovascular disease
The two medicines act differently to manage blood sugar
For hypoglycemia, which represents one of the more major possible side effects, immediate action is key
Drugs in this class In the UK, the following incretin mimetics are available for type 2 diabetic patients (trade name first, generic name in brackets): Bydureon (Exenatide) taken once weekly Byetta (Exenatide) taken twice daily Lyxumia (lixisenatide) taken once daily Trulicity (Dulaglutide) taken once weekly Victoza (Liraglutide) taken once daily Ozempic (Semaglutide) take once a week Byetta and Bydureon are the same medical drug
In 2018, the American Diabetes Association/European Association for the Study of Diabetes new consensus recommended GLP-1RAs as the first choice for glucose-lowering therapy in T2DM patients with ASCVD ( In the event of acute infection, the pro-inflammatory factor IL-6 can induce the secretion of GLP-1 to optimize the level of blood sugar ( DPP-4 knockout, the administration of GLP-1 RAs can increase cardiac cAMP levels, improve cardiovascular function in animals with endotoxemia, and improve the prognosis of endotoxemia ( Effect of GLP-1RAs on Blood Glucose in Patients With Sepsis L-cells that secrete GLP-1 are a type of multifunctional endocrine cells that only exist in the intestinal mucosal epithelium
+ Make sure you check our our related article, WHAT CAUSES A COMEDOWN
